Anti-Aging · Reference
ASCEND Blend Side Effects: Low Blood Sugar, Growth Hormone Effects and What to Report
This page is a practical reference: what each component contributes, what to watch, what to do and who should not take ASCEND. What the blend is and what research has looked at are in what is ASCEND and ASCEND blend benefits.
The side effects of the ASCEND blend are the side effects of its four components added together, and the one that needs the most attention is low blood sugar from IGF-1 LR3. Shakiness, sweating, sudden hunger, confusion or light-headedness after a dose mean eat something with sugar, then contact your care team. The commonest reports are injection-site redness or soreness, a brief flush, headache and hunger after the dose. Puffiness, joint aches and tingling hands are classic growth hormone effects that usually mean more growth hormone than a person needs, and they go to your care team rather than being pushed through. A personal or family history of cancer is treated as a reason not to use this blend.
This page is a practical reference: what each component contributes, what to watch, what to do and who should not take ASCEND. What the blend is and what research has looked at are in what is ASCEND and ASCEND blend benefits.
ASCEND Blend Side Effects
The short answer
| Side effect | Which component | How to read it | What to do |
|---|---|---|---|
| Low blood sugar: shakiness, sweating, sudden hunger, light-headedness, confusion | IGF-1 LR3 | Insulin-like effects; native IGF-1 caused hypoglycaemia in healthy adults | Eat or drink sugar, then contact your care team; severe or confused: 911 |
| Injection-site redness, soreness or a small lump | All four | The most common report | Rotate sites |
| Brief flush or warmth, headache, hunger after a dose | Mostly ipamorelin | Short-lived, mostly early | Report it if it persists |
| Puffiness, joint aches, hand tingling or numbness | Tesamorelin, CJC-1295, ipamorelin | Classic growth hormone effects; usually a dose signal | Message your care team; do not change the dose yourself |
| Raised blood sugar over time | Growth hormone from the secretagogues | Growth hormone reduces insulin sensitivity | Raise diabetes or borderline glucose at intake; report thirst and frequent urination |
| Growth signalling and the cancer question | IGF-1 LR3, and IGF-1 generally | Observational association; not shown to cause cancer | A personal or family history of cancer rules ASCEND out at Pepti |
| Facial or throat swelling, widespread hives, trouble breathing | Any injected peptide | Serious allergic reaction | Call 911 first, then tell your care team |
The product this page covers:
| Product | What is in it | Typical printed directions | Per dose | Price |
|---|---|---|---|---|
| ASCEND Blend | 6 mg CJC-1295, 12 mg ipamorelin, 10 mg tesamorelin and 1 mg IGF-1 LR3 in 5 mL | 0.25 mL (25 units) subcutaneously Monday through Friday nights at bedtime | 0.3 mg CJC-1295, 0.6 mg ipamorelin, 0.5 mg tesamorelin, 0.05 mg IGF-1 LR3 | $289/mo |
The per-dose figures are arithmetic from the vial's concentrations, on a U-100 insulin syringe; the full chart is in ASCEND blend dosage. Your physician sets your directions after reviewing your intake, and they are printed on the vial. The price is all-in: medication, physician review, refill management and shipping, with no membership fee. Compounded medications are not FDA approved.
ASCEND Blend Side Effects
Why a four-peptide blend has four sets of side effects
ASCEND has never been studied as a blend, so there is no side-effect data for it as a whole. What exists is per component, and it is uneven:
| Component | Per dose | Best safety source in the live research |
|---|---|---|
| Tesamorelin | 0.5 mg | The approved product's label, at 2 mg daily, four times ASCEND's amount |
| CJC-1295 | 0.3 mg | Small studies of the DAC form in healthy adults, described as well tolerated with no serious adverse reactions |
| Ipamorelin | 0.6 mg | A 1999 volunteer study and a seven-day surgical trial, both described as well tolerated |
| IGF-1 LR3 | 0.05 mg | No human trials; cautions carried over from native IGF-1 and its approved labelling |
The three secretagogues share one mechanism, a pulse of your own growth hormone, so their effects overlap rather than simply add. IGF-1 LR3 acts below the pituitary and brings its own, sharper, cautions. Because the ratio is fixed, a side effect from one component cannot be fixed by taking less of that one; your physician may revise your directions or choose a different product.
ASCEND Blend Side Effects
Low blood sugar: the first thing to know
Why it happens
IGF-1 and insulin are structurally related, and at high concentrations IGF-1 activates the insulin receptor as well as its own. A 1987 paper in the New England Journal of Medicine reported that recombinant native IGF-1 given to healthy adults produced hypoglycaemia. In the blood, more than 99 percent of native IGF-1 is held by binding proteins, which buffer that effect. IGF-1 LR3 is designed to escape those binding proteins, so it bypasses the buffer. At 0.05 mg per ASCEND dose the amount is small, but the direction of the risk is clear.
The signs and what to do
What you notice What it may be What to do Shakiness, sweating, sudden hunger, light-headedness Low blood sugar Eat or drink something with sugar now, then contact your care team Confusion, unusual behaviour, slurred speech More severe low blood sugar Eat or drink sugar if you can swallow safely; call 911 if it does not resolve quickly Unable to swallow safely, unresponsive, or a seizure Severe low blood sugar Someone with you should call 911 Repeated episodes, even mild ones A pattern your physician needs to know about Message your care team before the next dose Hunger after a dose is also an expected effect of ipamorelin, which acts at the receptor ghrelin, the hunger hormone, uses. With IGF-1 LR3 in the same vial, treat hunger with shakiness or sweating as possible low blood sugar until shown otherwise.
Who is at higher risk
Insulin and any other glucose-lowering medication are the interactions a physician asks about first. Diabetes, impaired glucose tolerance or a tendency to low blood sugar is raised at intake. Prescribers generally direct ASCEND away from food, because a rise in blood sugar blunts growth hormone release, and IGF-1 LR3 is the reason a physician may qualify that guidance for you. Follow the timing and food guidance in your own directions, and ask before the first dose if it is unclear.
ASCEND Blend Side Effects
Growth hormone effects from the three secretagogues
Puffiness, joint aches, swelling and tingling
Growth hormone makes the body hold more sodium and water. That shows up as puffy hands, ankles or face, joint aches, muscle aches and tingling or numbness in the hands, the classic carpal-tunnel pattern. On the approved tesamorelin label, at 2 mg daily, joint pain was reported by 13 percent against 11 percent on placebo, and muscle aches, peripheral swelling and pain in an arm or leg by 6 percent each, with tingling or numbness at 5 percent. Those rates belong to a higher dose of one component, not to ASCEND, but the pattern is the one to recognise. These effects usually mean the dose is higher than the person needs. The right response is a message to your care team, not pushing through and not changing the dose yourself.
Blood sugar over the longer term
Growth hormone also reduces insulin sensitivity, so the secretagogues can raise blood glucose, the opposite direction from IGF-1 LR3. The approved tesamorelin label records new-onset diabetes in 5 percent of treated patients against 1 percent on placebo, at 2 mg daily. Thirst, frequent urination or unexplained tiredness are worth reporting. Diabetes or borderline glucose is raised at intake.
Flush, headache and dreams
A brief flush or head-rush within minutes of dosing, light-headedness and headache, mostly early in a course, are described with ipamorelin and other growth-axis peptides. Vivid dreams are reported with evening dosing. Sleep is what people most often describe noticing first. None of these is usually a reason for concern unless it persists or sleep is worse.
Injection-site reactions
The commonest complaint across the components. On the tesamorelin label, injection-site reactions were reported by 17 percent against 6 percent on placebo. Rotate sites between the abdomen and thigh. A site that is hotter, larger or more painful at 48 hours than at 24 hours can be infection rather than irritation and needs a same-day message. Technique is in how to inject peptides safely.
ASCEND Blend Side Effects
Growth signalling and the cancer question
IGF-1 promotes the growth and survival of cells, not only muscle cells. A 2004 systematic review in the Lancet reported that higher circulating IGF-1 in the general population was associated with a higher risk of prostate, premenopausal breast and colorectal cancer. That is an association in observational data about the native hormone, not a demonstration that IGF-1 causes cancer. The approved tesamorelin product is contraindicated in active malignancy, and the approved native IGF-1 product in anyone with a malignancy or a history of one. In ASCEND, both the secretagogues (which raise IGF-1) and IGF-1 LR3 (which supplies an IGF-1 signal directly) point the same way. The prudent reading is that a personal or family history of cancer is a reason not to use this blend, and Pepti's intake treats it that way. The broader question is in can peptides cause cancer.
ASCEND Blend Side Effects
Other considerations
| Consideration | Detail |
|---|---|
| Your own growth hormone output | IGF-1 is the signal the pituitary reads; supplying it from outside turned the body's own output down in animal work. No human data on this |
| Drug metabolism | Growth hormone can alter cytochrome P450 metabolism, so the intake asks for everything you take |
| Approved native IGF-1 labelling | Lists lymphoid tissue swelling, raised pressure inside the skull (headache with visual change) and joint pain, mostly in children; unknown for adults on the analogue |
| Quality | The FDA has raised a general concern about immunogenicity with injectable compounded peptides; lot test results are at /quality/lab-results |
| Long-term safety | Not established for the blend or for continuous use of any component |
There is no established interaction list for ASCEND or any of its components beyond the note on drug metabolism, which is why a physician reviews every medication you take.
ASCEND Blend Side Effects
When to message your care team
- Any episode of shakiness, sweating, sudden hunger or light-headedness after a dose, even if it passed.
- Puffiness, joint aches, or tingling or numbness in the hands.
- Thirst, frequent urination or unexplained tiredness.
- A headache that persists, or any change in vision.
- Injection-site redness or swelling that spreads or does not settle.
- A new lump anywhere, or a diagnosis of diabetes or any cancer.
- You start any new medication, especially anything that lowers blood sugar.
- Your label and your syringe seem not to match. Do not inject; ask first.
Do not change your own dose, skip doses to manage a side effect, or take two doses to make up for a missed one. Your physician sets your directions after reviewing how you are doing, and any change is printed on the next label.
ASCEND Blend Side Effects
When to get emergency care
| Symptom | What it may be | What to do |
|---|---|---|
| Confusion, a seizure, or being unable to eat or drink safely | Severe low blood sugar | Call 911 |
| Swelling of the face, lips or throat, widespread hives, trouble breathing | Serious allergic reaction | Call 911 first, then tell your care team |
| A severe headache with visual change | Possible raised pressure inside the skull | Same-day urgent care; call 911 if severe or with confusion |
| You think you injected far more than your directions | Possible overdose, with a high risk of low blood sugar | Eat something with sugar, call Poison Control at 1-800-222-1222, and message your care team; call 911 for any confusion or drowsiness |
ASCEND Blend Side Effects
Who should not take ASCEND, or should discuss it first
| Situation | Status |
|---|---|
| Personal or family history of cancer | Treated as a reason not to prescribe |
| Diabetes, impaired glucose tolerance or a tendency to low blood sugar | Raised at intake; often a reason to choose a blend without IGF-1 LR3 |
| Taking insulin or another glucose-lowering medication | Not prescribed without a specific plan |
| A pituitary disorder or disrupted hypothalamic-pituitary axis | Raised at intake |
| Pregnancy or breastfeeding | Not used; safety data is absent |
| Tested athletes | GHRH analogues, growth hormone secretagogues and IGF-1 analogues are prohibited in sport |
| Under 18 | Pepti prescribes to adults only |
Where the IGF-1 LR3 cautions are the problem, TITAN keeps tesamorelin, CJC-1295 and ipamorelin and swaps IGF-1 LR3 for BPC-157, and CJC-1295 / Ipamorelin is the two-signal pairing alone. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.
ASCEND Blend Side Effects
What the evidence shows, honestly
No study has looked at ASCEND's side effects, because no study has looked at ASCEND. The picture on this page is assembled from the approved tesamorelin label at four times ASCEND's tesamorelin, small and well tolerated human studies of CJC-1295 and ipamorelin, what native IGF-1 did in people, and what prescribers report. The secretagogue effects are familiar and usually mean a dose is more than a person needs. The IGF-1 LR3 cautions, low blood sugar and the cancer question, are sharper, and nothing shows the analogue is exempt from them. Component by component: tesamorelin side effects, ipamorelin side effects, is CJC-1295 / Ipamorelin safe and IGF-1 LR3 side effects.
ASCEND Blend Side Effects
Where to get ASCEND prescribed
ASCEND cannot be bought legitimately without a prescription. Products sold "for research use only" have no accountable pharmacy behind their identity, purity, sterility or concentration. The prescription route:
- Complete a free online intake covering your history, medications, blood sugar, cancer and family history, and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with ice packs, with sterile syringes and alcohol prep pads, and your directions printed on the vial.
- Your care team stays reachable for side effects and questions. Refills run every 28 days, one vial per fill.
Pepti is cash-pay and does not bill insurance, and prescribes ASCEND in every state except Oklahoma, plus DC
References
What this is based on.
References
- Falutz J, Allas S, Blot K et al.. Metabolic effects of a growth hormone-releasing factor in patients with HIV · N Engl J Med (2007) · PMID 18057338
- Raun K, Hansen BS, Johansen NL et al.. Ipamorelin, the first selective growth hormone secretagogue · Eur J Endocrinol (1998) · PMID 9849822
- Teichman SL, Neale A, Lawrence B et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · J Clin Endocrinol Metab (2006) · PMID 16352683
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
ASCEND Blend Side Effects, answered.
Most commonly injection-site redness or soreness, a brief flush, headache and hunger after a dose. Puffiness, joint aches and tingling hands signal more growth hormone than a person needs. The one that matters most is low blood sugar from the IGF-1 LR3 component.
It can. IGF-1 has insulin-like effects, and IGF-1 LR3 is designed to escape the binding proteins that buffer them. Shakiness, sweating, sudden hunger or light-headedness after a dose mean eat something with sugar, then contact your care team.
Over time, yes. Growth hormone from the three secretagogues reduces insulin sensitivity, and the approved tesamorelin label records new-onset diabetes in 5 percent of treated patients against 1 percent on placebo at 2 mg daily. Report thirst or frequent urination.
Puffiness and fluid retention are classic growth hormone effects from the secretagogues. They usually mean the dose is more than you need. Message your care team rather than changing the dose yourself.
Soft-tissue swelling at the wrist from growth hormone, the classic carpal-tunnel pattern. Message your care team.
Ipamorelin acts at the receptor the hunger hormone ghrelin uses, so hunger is expected. With IGF-1 LR3 in the vial, hunger with shakiness or sweating should be treated as possible low blood sugar.
Nobody has shown that it does. Higher circulating IGF-1 has been associated with several cancers in observational research, and the approved tesamorelin and native IGF-1 products carry malignancy contraindications. A personal or family history of cancer is treated as a reason not to prescribe ASCEND.
The IGF-1 LR3 per dose is the same 50 mcg in both, so its cautions apply in full. ASCEND adds the growth hormone effects of three secretagogues on top.
TITAN has the same tesamorelin, CJC-1295 and ipamorelin per dose and swaps IGF-1 LR3 for BPC-157, so it does not carry the IGF-1 LR3 low blood sugar and growth-signalling cautions. It still has the growth hormone effects.
Eat or drink something with sugar, call Poison Control at 1-800-222-1222, and message your care team. Call 911 for any confusion, drowsiness, a seizure, or inability to swallow safely.
GHRH analogues, growth hormone secretagogues and IGF-1 analogues are prohibited in sport, and a prescription does not change that. See do peptides show up on a drug test. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.